title: Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.
abstract: Doxorubicin (DXR) is a frontline chemotherapy agent implicated in unintended ovarian failure in female cancer survivors. The fertility preservation techniques currently available for cancer patients are often time and cost prohibitive and do not necessarily preserve endocrine function. There are no drug-based ovary protection therapies clinically available. This study provides the first investigation using dexrazoxane (Dexra) to limit DXR insult in ovarian tissue. In KK-15 granulosa cells, a 3-h DXR treatment increased double-strand (ds) DNA breaks 40%-50%, as quantified by the neutral comet assay, and dose-dependent cytotoxicity. Dexra exhibited low toxicity in KK-15 cells, inducing no DNA damage and less than 20% cell loss. Cotreating KK-15 cells with Dexra prevented acute DXR-induced dsDNA damage. Similarly, Dexra attenuated the DXR-induced 40%-65% increase in dsDNA breaks in primary murine granulosa cells and cells from in vitro cultured murine ovaries. DXR can cause DNA damage either through a topoisomerase II-mediated pathway, based on DXR intercalation into DNA, or through oxidative stress. Cotreating KK-15 cells with 2 μM Dexra was sufficient to prevent DXR-induced, but not H(2)O(2)-induced, DNA damage. These data indicated the protective effects are likely due to Dexra's inhibition of topoisomerase II catalytic activity. This putative protective agent attenuated downstream cellular responses to DXR, preventing H2AFX activation in KK-15 cells and increasing viability as demonstrated by increasing the DXR lethal dose in KK-15 cells 5- to 8-fold (LD(20)) and primary murine granulosa cells 1.5- to 2-fold (LD(50)). These data demonstrate Dexra protects ovarian cells from DXR insult and suggest that it is a promising tool to limit DXR ovarian toxicity in vivo.
authors.affiliation: REI Division, Department of Obstetrics & Gynecology, University of Wisconsin-Madison, Madison, Wisconsin 53705, USA.
authors.forename: Elon C
authors.initials: EC
authors.lastname: Roti Roti
authors.forename: Sana M
authors.initials: SM
authors.lastname: Salih
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002478:Cells, Cultured; D004249:DNA Damage / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006107:Granulosa Cells / Q000166:cytology / Q000187:drug effects; D006657:Histones / Q000037:antagonists & inhibitors / Q000502:physiology; D006861:Hydrogen Peroxide / Q000494:pharmacology; D007247:Infertility, Female / Q000517:prevention & control*; D051379:Mice; D008815:Mice, Inbred Strains; D023421:Models, Animal; D010053:Ovary / Q000166:cytology / Q000187:drug effects*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D011929:Razoxane / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004250:DNA Topoisomerases, Type II; D004317:Doxorubicin; D006657:Histones; D006861:Hydrogen Peroxide; D011929:Razoxane; C475961:gamma-H2AX protein, mouse